The DOI matches its Crossref record.
Antibody‐Mediated Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d as Markers
Open accessAbstract
Antibody-mediated rejection (AMR) in human heart transplantation is an immunopathologic process in which injury to the graft is in part the result of activation of complement and it is poorly responsive to conventional therapy. We evaluated by immunofluorescence (IF), 665 consecutive endomyocardial biopsies from 165 patients for deposits of immunoglobulins and complement. Diffuse IF deposits in a linear capillary pattern greater than 2+ were considered significant. Clinical evidence of graft dysfunction was correlated with complement deposits. IF 2+ or higher was positive for IgG, 66%; IgM, 12%; IgA, 0.6%; C1q, 1.8%; C4d, 9% and C3d, 10%. In 3% of patients, concomitant C4d and C3d correlated with graft dysfunction or heart failure. In these 5 patients AMR occurred 56-163 months after transplantation, and they responded well to therapy for AMR but not to treatment with steroids. Systematic evaluation of endomyocardial biopsies is not improved by the use of antibodies for immunoglobulins or C1q. Concomitant use of C4d and C3d is very useful to diagnose AMR, when correlated with clinical parameters of graft function. AMR in heart transplant patients can occur many months or years after transplant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 485
Colvin, M. M., Cook, J. L., Chang, P., Francis, G., Hsu, D. T., Kiernan, M. S., Kobashigawa, J. A., Lindenfeld, J., Masri, S. C., Miller, D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000093 · Cited by 376
Self-citationReport from a consensus conference on antibody-mediated rejection in heart transplantation
Kobashigawa, J., Crespo-Leiro, M. G., Ensminger, S. M., Reichenspurner, H., Angelini, A., Berry, G., Burke, M., Czer, L., Hiemann, N., Kfoury, A. G., et al. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.11.003 · Cited by 368
Self-citationImmune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 299
The changing face of heart transplantation
Hunt, S. A., & Haddad, F. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.020 · Cited by 225
Metadata
- Authors
- Rodriguez, E. R., Skojec, D. V., Tan, C. D., Zachary, A. A., Kasper, E. K., Conte, J. V., & Baldwin, W. M.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 5
- Issue
- 11
- Pages
- 2778-2785
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1995278765
- Cited by
- 162
- References
- 0
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody‐Mediated Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d as Markers. https://app.cochat.ai/papers/10.1111/j.1600-6143.2005.01074.x
- The paper
- Rodriguez, E. R., Skojec, D. V., Tan, C. D., Zachary, A. A., Kasper, E. K., Conte, J. V., & Baldwin, W. M. (2005). Antibody‐Mediated Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d as Markers. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2005.01074.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.